Xsolla SPAC 1, a blank check company led by executives from video game fintech Xsolla, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-half of one warrant exercisable at $11.50 per share. The ...read more
United Acquisition I, a blank check company led by Globis Capital Advisors founder Paul Packer, raised $100 million by offering 10 million units at $10. Each unit consists of one ordinary share and one-quarter of one warrant, exercisable at $11.50 per...read more
AgomAb Therapeutics, a Belgian Phase 2 biotech developing TGFβ inhibitors for Crohn's and other fibrotic diseases, announced terms for its IPO on Thursday. The Antwerp, Belgium-based company plans to raise $200 million by offering 12.5 million shares at a ...read more
Xsolla SPAC 1 prices downsized $200 million IPO, led by the founder of video game fintech Xsolla
Xsolla SPAC 1, a blank check company led by executives from video game fintech Xsolla, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-half of one warrant exercisable at $11.50 per share. The ...read more
SPAC United Acquisition I prices $100 million IPO; led by Paul Packer, whose previous SPAC merged with Forafric
United Acquisition I, a blank check company led by Globis Capital Advisors founder Paul Packer, raised $100 million by offering 10 million units at $10. Each unit consists of one ordinary share and one-quarter of one warrant, exercisable at $11.50 per...read more
Belgian fibrotic disease biotech AgomAb Therapeutics sets terms for $200 million US IPO
AgomAb Therapeutics, a Belgian Phase 2 biotech developing TGFβ inhibitors for Crohn's and other fibrotic diseases, announced terms for its IPO on Thursday. The Antwerp, Belgium-based company plans to raise $200 million by offering 12.5 million shares at a ...read more